Best Healthcare Stocks to Buy in 2026
(NASDAQ: BIIB) and Novo Nordisk (NYSE: NVO) represent different opportunities within the healthcare sector: One is a value-oriented play focusing on specialized neurology, while the other is a high-growth leader in the metabolic health revolution. However, both pharmaceutical companies stand to benefit from new indications for approved therapies that haven't fully been priced into their shares.
Biogen is awaiting approval of Leqembi in a subcutaneous formulation to treat Alzheimer's patients; the drug is already approved in intravenous (IV) formulations. Novo Nordisk is seeing an uptick in Wegovy sales because its weight-loss therapy is now available in pill form. Biogen's shares are trading up more than 13.5% this year, while Novo Nordisk's are down almost 8%.
Here are three reasons why I like each stock.
Source Fool.com
Biogen Inc. Stock
With 41 Buy predictions and 1 Sell predictions Biogen Inc. is one of the favorites of our community.
As a result the target price of 204 € shows a slightly positive potential of 11.23% compared to the current price of 183.4 € for Biogen Inc..
